# FDA seeks input on safeguards for early ibogaine trials

> The agency is asking about trial design, dosing, safety monitoring and oversight, with comments due November 20.

- Canonical URL: https://newsverum.com/en/news/fda-seeks-input-on-ibogaine-clinical-trial-design
- Publisher: Newsverum
- Section: Health
- Country: United States
- Published: 2026-10-06T17:58:49+00:00
- Updated: 2026-10-07T00:52:01+03:00
- Event / data period: 2026-10-05
- Other editions: [Türkçe](https://newsverum.com/tr/news/fda-seeks-input-on-ibogaine-clinical-trial-design.md), [العربية](https://newsverum.com/ar/news/fda-seeks-input-on-ibogaine-clinical-trial-design.md), [Français](https://newsverum.com/fr/news/fda-seeks-input-on-ibogaine-clinical-trial-design.md), [Español](https://newsverum.com/es/news/fda-seeks-input-on-ibogaine-clinical-trial-design.md), [Deutsch](https://newsverum.com/de/news/fda-seeks-input-on-ibogaine-clinical-trial-design.md), [Português](https://newsverum.com/pt/news/fda-seeks-input-on-ibogaine-clinical-trial-design.md)

The FDA issued a request for information on how early-phase clinical trials of ibogaine products should be designed. It is seeking evidence and feedback on patient eligibility, dose escalation, care settings, stopping rules, safety monitoring and independent oversight.

The agency highlighted cardiac and neurologic risks and said a proposed starting dose should be supported by available evidence and not exceed 10 milligrams per kilogram. The request is for input on research design, not an approval of ibogaine treatment; the comment period is scheduled to close November 20, 2026.

## Data

### FDA information request and comment timeline

The FDA information request and deadline stated in the release.

Methodology: The date and action are transcribed from FDA. The future deadline is source-stated and does not indicate a drug approval or trial result.

| date | label | description | status |
|---|---|---|---|
| 2026-10-05 | FDA information request issued | Request for views and data on early ibogaine trial design. | occurred |
| 2026-11-20 | Comment period closes | FDA says late comments will not be considered. | scheduled |

Sources: <https://www.fda.gov/news-events/press-announcements/fda-seeks-public-input-support-ibogaine-research> · Download data: [JSON](https://newsverum.com/api/v1/articles/fda-seeks-input-on-ibogaine-clinical-trial-design/data/ibogaine-rfi-timeline?lang=en&format=json) · [CSV](https://newsverum.com/api/v1/articles/fda-seeks-input-on-ibogaine-clinical-trial-design/data/ibogaine-rfi-timeline?lang=en&format=csv)

## Sources

- [U.S. Food and Drug Administration](<https://www.fda.gov/news-events/press-announcements/fda-seeks-public-input-support-ibogaine-research>) (Source checked: 2026-10-06; Published: 2026-10-05)

## Correction history

- 2026-10-07T00:52:01+03:00: German and Portuguese editions and translations of the data and correction explanations have been added to this article.

---

Cite the canonical URL above. [Editorial standards and corrections](https://newsverum.com/en/editorial)